Article
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2006
Endoh Hideki, Yatabe Yasushi, Kosaka Takayuki, Kuwano Hiroyuki, Mitsudomi Tetsuya
Abstract excerpt
BACKGROUND: We and other researchers have previously reported that pulmonary adenocarcinomas with epidermal growth factor receptor (EGFR) mutations are usually sensitive to gefitinib, an EGFR-specific tyrosine kinase inhibitor, although this relationship is not complete. In this study, we searched for mutations or changes in the expression of genes downstream to EGFR and evaluated their relationship with the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
